Form 4: Guardant Health Director Converts Restricted Stock Units to Common Shares

Guardant Health, Inc. Director Manuel Hidalgo Medina acquired 2,784 common shares through the vesting of restricted stock units on July 17, 2025, as part of a previously granted equity award.

Summary

• Manuel Hidalgo Medina, a Director at Guardant Health, Inc. (GH), acquired 2,784 shares of common stock on July 17, 2025.
• This acquisition resulted from the vesting of Restricted Stock Units (RSUs) at a price of $0 per share.
• The RSUs were originally granted on July 17, 2024.
• The vesting schedule for the RSU award is 25% on the one-year anniversary of the grant (July 17, 2025), with the remaining 75% vesting monthly over the subsequent three-year period.
• Following this transaction, Manuel Hidalgo Medina directly beneficially owns 2,784 shares of common stock and 8,353 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing indicates a routine RSU vesting event for a director, which is a neutral to slightly positive signal as it reflects ongoing executive compensation and retention, aligning interests with shareholders. It does not contain any negative surprises or significant new information.

Positives

• The vesting of Restricted Stock Units indicates continued executive compensation and retention, aligning management's interests with shareholders.
• The acquisition of shares by a director demonstrates ongoing commitment to the company.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The remaining 75% of the Restricted Stock Units granted on July 17, 2024, are scheduled to vest monthly over the three-year period following the initial one-year anniversary vesting.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation, which is a common practice across the biotechnology and healthcare technology industries to incentivize and retain key personnel. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The vesting of RSUs increases the outstanding share count slightly over time, which can lead to minor dilution. However, it also aligns the director's interests with shareholder value creation.
• Employees: This filing pertains to a director's equity compensation and does not directly impact the broader employee base, though it reflects standard compensation practices.

Next Steps

• Future monthly vesting of the remaining 75% of the Restricted Stock Units over the next three years.

Key Dates

Recommendation

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Compensation, Equity Award, Manuel Hidalgo Medina